These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 34464833

  • 1. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis.
    Soni P, Chawla E.
    Clin Neurol Neurosurg; 2021 Oct; 209():106893. PubMed ID: 34464833
    [Abstract] [Full Text] [Related]

  • 2. Quality of Life Related to Functional Disability in Migraine Patients: A Systematic Review and Network Meta-analysis.
    Soni P, Chawla E.
    Clin J Pain; 2021 Nov 01; 37(11):845-851. PubMed ID: 34419975
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U.
    CNS Drugs; 2021 Aug 01; 35(8):805-820. PubMed ID: 34272688
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis.
    Wang X, Wen D, He Q, You C, Ma L.
    J Headache Pain; 2022 Sep 08; 23(1):105. PubMed ID: 36071388
    [Abstract] [Full Text] [Related]

  • 7. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y, Liu Y, Zhao J, Han Q, Liu L, Shen X.
    Neurol Sci; 2018 Dec 08; 39(12):2097-2106. PubMed ID: 30182284
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F, Braca S, Sansone M, Miele A, Stornaiuolo A, De Simone R, Russo CV.
    Headache; 2023 Jun 08; 63(6):788-794. PubMed ID: 37254581
    [Abstract] [Full Text] [Related]

  • 18. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F, Bolchini M, Ceccardi G, Caratozzolo S, Liberini P, Rao R, Padovani A.
    Eur J Neurol; 2023 Jun 08; 30(6):1764-1773. PubMed ID: 36856538
    [Abstract] [Full Text] [Related]

  • 19. Monoclonal antibodies against calcitonin gene-related peptide in chronic migraine: an adjusted indirect treatment comparison.
    Briceño-Casado MDP, Gil-Sierra MD, Fénix-Caballero S.
    Farm Hosp; 2020 Aug 21; 44(5):212-217. PubMed ID: 32853126
    [Abstract] [Full Text] [Related]

  • 20. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
    Nagaraj K, Vandenbussche N, Goadsby PJ.
    Neurol India; 2021 Aug 21; 69(Supplement):S59-S66. PubMed ID: 34003149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.